BioCentury | Jan 6, 2021
Deals

Jan. 5 Quick Takes: Myriad restructuring; plus ViGeneron-Biogen, Rhythm, Sosei and more

...Leptin receptorPCSK1 – Proprotein convertase subtilisin/kexin type 1POMC – Proopiomelanocortin BC Staff HGH-CTP, Lagova, somatrogon (MOD-4023, PF-06836922) Myriad Genetics ViGeneron Biogen Rhythm Pharmaceuticals Sosei Nirmidas...
BioCentury | Dec 23, 2020
Product Development

Dec. 21-23 Quick Takes: readouts for Genentech, Rhythm, ChemoCentryx and BMS

...2021 meeting in February. Rhythm’s MC4F agonist meets in Phase III for rare obesity conditionImcivree setmelanotide from Rhythm Pharmaceuticals Inc....
BioCentury | Nov 5, 2020
Management Tracks

Rosén joins Horizon as CSO and R&D head; plus moves at Boehringer, Dr. Reddy’s, Mylan and more

...Nov. 30. Nacht was CSO of Vivid Biosciences. Jennifer Chien joined rare genetic obesity disorder company Rhythm Pharmaceuticals Inc....
...Neuroscience Inc. and Gossamer Bio Inc. (NASDAQ:GOSS). Danielle Golovin Boehringer Ingelheim Horizon Therapeutics plc GlaxoSmithKline plc Dr. Reddy's Laboratories Ltd. Mylan N.V. Rhythm Pharmaceuticals Inc. Silence...
BioCentury | Sep 16, 2020
Management Tracks

O’Brien to lead Tizona in wake of Gilead deal; plus Silence, PacBio, Rhythm

...CFO Susan Kim has joined Pacific Biosciences of California Inc. (NASDAQ:PACB) as CFO.Yann Mazabraud will join Rhythm Pharmaceuticals Inc....
...officer and head of international for the past two years. Jeff Cranmer Tizona Therapeutics Inc. Silence Therapeutics plc Pacific Biosciences Rhythm Pharmaceuticals Inc....
BioCentury | Aug 5, 2020
Management Tracks

CureVac makes Haas’ CEO job permanent; plus Zhang now CEO of Legend and updates from Royalty, NBE, Black Diamond, VelosBio and more

...a new position. He was president of global commercial at Acelity L.P. Inc. Obesity company Rhythm Pharmaceuticals Inc....
...Biotech Corp. Royalty Pharma plc NBE-Therapeutics AG Black Diamond Therapeutics Inc. VelosBio Inc. Aspen Neuroscience Inc. Humanigen Inc. Engrail Therapeutics Inc. MiMedx Group Inc. Rhythm Pharmaceuticals Inc. Sierra...
BioCentury | Jul 22, 2020
Management Tracks

Meeker expands role at Rhythm; plus Biogen, Kronos, Citryll, Akcea, ImmunoGen, Circle, Antares and more

...David Meeker will become president and CEO of obesity company Rhythm Pharmaceuticals Inc. (NASDAQ:RYTM) while remaining chairman, a...
...NYSE:MDT). MannKind is developing inhaled therapeutics for diabetes and orphan lung diseases. Robin Sawka, BioCentury Staff Biogen Inc. Rhythm Pharmaceuticals Kronos...
BioCentury | May 30, 2020
Product Development

Sorting out COVID-19 consortia

...least R&D leaders of 15 biopharma companies, two VCs and Keith Gottesdiener, former CEO of Rhythm Pharmaceuticals Inc....
...U.K. called COVID-19 Genomics UK (COG-UK). Danielle Kopke, Staff Writer AZD1222, ChAdOx1 nCov-19 (ChAdOx1) Bill & Melinda Gates Foundation FNIH NIH Rhythm Pharmaceuticals Inc. Wellcome...
BioCentury | May 19, 2020
Product Development

May 18 Quick Takes: ChemoCentryx’s Phase II miss; plus Teva, Zai-Novocure, Lava-J&J, Sanofi, Rhythm, ViiV

...for Rare Anemia” ). Priority Review for Rhythm’s obesity treatment An NDA for setmelanotide from Rhythm Pharmaceuticals Inc....
BioCentury | Apr 18, 2020
Politics, Policy & Law

Collaborating to clobber COVID-19

...leaders of 15 companies, two VCs and one unaffiliated individual, Keith Gottesdiener, former CEO of Rhythm Pharmaceuticals Inc....
BioCentury | Apr 16, 2020
Deals

COVID R&D: Pharmas align behind crowdsourcing solution

...a veteran of Merck & Co. Inc. (NYSE:MRK), stepped down as president and CEO of Rhythm Pharmaceuticals Inc....
...of development, GlaxoSmithKline plc Jerel Davis, managing director, Versant Ventures Keith Gottesdiener, independent (former CEO, Rhythm Pharmaceuticals...
Items per page:
1 - 10 of 89
BioCentury | Jan 6, 2021
Deals

Jan. 5 Quick Takes: Myriad restructuring; plus ViGeneron-Biogen, Rhythm, Sosei and more

...Leptin receptorPCSK1 – Proprotein convertase subtilisin/kexin type 1POMC – Proopiomelanocortin BC Staff HGH-CTP, Lagova, somatrogon (MOD-4023, PF-06836922) Myriad Genetics ViGeneron Biogen Rhythm Pharmaceuticals Sosei Nirmidas...
BioCentury | Dec 23, 2020
Product Development

Dec. 21-23 Quick Takes: readouts for Genentech, Rhythm, ChemoCentryx and BMS

...2021 meeting in February. Rhythm’s MC4F agonist meets in Phase III for rare obesity conditionImcivree setmelanotide from Rhythm Pharmaceuticals Inc....
BioCentury | Nov 5, 2020
Management Tracks

Rosén joins Horizon as CSO and R&D head; plus moves at Boehringer, Dr. Reddy’s, Mylan and more

...Nov. 30. Nacht was CSO of Vivid Biosciences. Jennifer Chien joined rare genetic obesity disorder company Rhythm Pharmaceuticals Inc....
...Neuroscience Inc. and Gossamer Bio Inc. (NASDAQ:GOSS). Danielle Golovin Boehringer Ingelheim Horizon Therapeutics plc GlaxoSmithKline plc Dr. Reddy's Laboratories Ltd. Mylan N.V. Rhythm Pharmaceuticals Inc. Silence...
BioCentury | Sep 16, 2020
Management Tracks

O’Brien to lead Tizona in wake of Gilead deal; plus Silence, PacBio, Rhythm

...CFO Susan Kim has joined Pacific Biosciences of California Inc. (NASDAQ:PACB) as CFO.Yann Mazabraud will join Rhythm Pharmaceuticals Inc....
...officer and head of international for the past two years. Jeff Cranmer Tizona Therapeutics Inc. Silence Therapeutics plc Pacific Biosciences Rhythm Pharmaceuticals Inc....
BioCentury | Aug 5, 2020
Management Tracks

CureVac makes Haas’ CEO job permanent; plus Zhang now CEO of Legend and updates from Royalty, NBE, Black Diamond, VelosBio and more

...a new position. He was president of global commercial at Acelity L.P. Inc. Obesity company Rhythm Pharmaceuticals Inc....
...Biotech Corp. Royalty Pharma plc NBE-Therapeutics AG Black Diamond Therapeutics Inc. VelosBio Inc. Aspen Neuroscience Inc. Humanigen Inc. Engrail Therapeutics Inc. MiMedx Group Inc. Rhythm Pharmaceuticals Inc. Sierra...
BioCentury | Jul 22, 2020
Management Tracks

Meeker expands role at Rhythm; plus Biogen, Kronos, Citryll, Akcea, ImmunoGen, Circle, Antares and more

...David Meeker will become president and CEO of obesity company Rhythm Pharmaceuticals Inc. (NASDAQ:RYTM) while remaining chairman, a...
...NYSE:MDT). MannKind is developing inhaled therapeutics for diabetes and orphan lung diseases. Robin Sawka, BioCentury Staff Biogen Inc. Rhythm Pharmaceuticals Kronos...
BioCentury | May 30, 2020
Product Development

Sorting out COVID-19 consortia

...least R&D leaders of 15 biopharma companies, two VCs and Keith Gottesdiener, former CEO of Rhythm Pharmaceuticals Inc....
...U.K. called COVID-19 Genomics UK (COG-UK). Danielle Kopke, Staff Writer AZD1222, ChAdOx1 nCov-19 (ChAdOx1) Bill & Melinda Gates Foundation FNIH NIH Rhythm Pharmaceuticals Inc. Wellcome...
BioCentury | May 19, 2020
Product Development

May 18 Quick Takes: ChemoCentryx’s Phase II miss; plus Teva, Zai-Novocure, Lava-J&J, Sanofi, Rhythm, ViiV

...for Rare Anemia” ). Priority Review for Rhythm’s obesity treatment An NDA for setmelanotide from Rhythm Pharmaceuticals Inc....
BioCentury | Apr 18, 2020
Politics, Policy & Law

Collaborating to clobber COVID-19

...leaders of 15 companies, two VCs and one unaffiliated individual, Keith Gottesdiener, former CEO of Rhythm Pharmaceuticals Inc....
BioCentury | Apr 16, 2020
Deals

COVID R&D: Pharmas align behind crowdsourcing solution

...a veteran of Merck & Co. Inc. (NYSE:MRK), stepped down as president and CEO of Rhythm Pharmaceuticals Inc....
...of development, GlaxoSmithKline plc Jerel Davis, managing director, Versant Ventures Keith Gottesdiener, independent (former CEO, Rhythm Pharmaceuticals...
Items per page:
1 - 10 of 89